Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $16.94 in the prior trading day, 10x Genomics Inc (NASDAQ: TXG) closed at $16.5, down -2.60%. In other words, the price has decreased by -$2.60 from its previous closing price. On the day, 2.29 million shares were traded. TXG stock price reached its highest trading level at $16.74 during the session, while it also had its lowest trading level at $16.11.
Ratios:
Our goal is to gain a better understanding of TXG by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.59. For the most recent quarter (mrq), Quick Ratio is recorded 4.06 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On December 02, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $20. On September 11, 2025, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $15.Piper Sandler initiated its Neutral rating on September 11, 2025, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 24 ’25 when Taich Adam sold 11,888 shares for $19.00 per share. The transaction valued at 225,852 led to the insider holds 297,385 shares of the business.
Hindson Benjamin J. sold 8,283 shares of TXG for $157,363 on Nov 24 ’25. The insider now owns 432,605 shares after completing the transaction at $19.00 per share. On Nov 24 ’25, another insider, Saxonov Serge, who serves as the Chief Executive Officer of the company, sold 13,261 shares for $19.00 each. As a result, the insider received 251,936 and left with 1,021,556 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 2088125312 and an Enterprise Value of 1693026304. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.25 while its Price-to-Book (P/B) ratio in mrq is 2.66. Its current Enterprise Value per Revenue stands at 2.638 whereas that against EBITDA is -17.365.
Stock Price History:
The Beta on a monthly basis for TXG is 2.18, which has changed by 0.15473759 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $20.34, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is 6.27%, while the 200-Day Moving Average is calculated to be 35.51%.
Shares Statistics:
The stock has traded on average 2.79M shares per day over the past 3-months and 2300630 shares per day over the last 10 days, according to various share statistics. A total of 116.46M shares are outstanding, with a floating share count of 112.05M. Insiders hold about 11.46% of the company’s shares, while institutions hold 96.95% stake in the company. Shares short for TXG as of 1764288000 were 14803796 with a Short Ratio of 5.31, compared to 1761868800 on 15016478. Therefore, it implies a Short% of Shares Outstanding of 14803796 and a Short% of Float of 18.59.
Earnings Estimates
The market rating for 10x Genomics Inc (TXG) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.08 and low estimates of -$0.28.
Analysts are recommending an EPS of between $0.46 and -$0.49 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is -$0.41, with 3.0 analysts recommending between -$0.08 and -$0.9.
Revenue Estimates
15 analysts predict $156.01M in revenue for. The current quarter. It ranges from a high estimate of $157.2M to a low estimate of $154.1M. As of. The current estimate, 10x Genomics Inc’s year-ago sales were $165.02MFor the next quarter, 15 analysts are estimating revenue of $142.61M. There is a high estimate of $149.1M for the next quarter, whereas the lowest estimate is $135.85M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $634M, while the lowest revenue estimate was $630.9M, resulting in an average revenue estimate of $632.81M. In the same quarter a year ago, actual revenue was $610.78MBased on 16 analysts’ estimates, the company’s revenue will be $610.6M in the next fiscal year. The high estimate is $621.3M and the low estimate is $596M.
